IL307974A - Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor - Google Patents

Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor

Info

Publication number
IL307974A
IL307974A IL307974A IL30797423A IL307974A IL 307974 A IL307974 A IL 307974A IL 307974 A IL307974 A IL 307974A IL 30797423 A IL30797423 A IL 30797423A IL 307974 A IL307974 A IL 307974A
Authority
IL
Israel
Prior art keywords
akr1c3
activated
compound
combination therapy
immune checkpoint
Prior art date
Application number
IL307974A
Other languages
English (en)
Hebrew (he)
Inventor
Ming-Tain Lai
wan-fen Li
Chun-Chung Wang
Lu-Tzu Chen
Original Assignee
Obi Pharma Inc
Lai Ming Tain
Li Wan Fen
Wang Chun Chung
Chen Lu Tzu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc, Lai Ming Tain, Li Wan Fen, Wang Chun Chung, Chen Lu Tzu filed Critical Obi Pharma Inc
Publication of IL307974A publication Critical patent/IL307974A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL307974A 2021-04-28 2021-04-28 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor IL307974A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/029552 WO2022231580A1 (en) 2021-04-28 2021-04-28 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
IL307974A true IL307974A (en) 2023-12-01

Family

ID=83847212

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307974A IL307974A (en) 2021-04-28 2021-04-28 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor

Country Status (10)

Country Link
US (1) US20240216401A1 (enExample)
EP (1) EP4329745A4 (enExample)
JP (1) JP7875886B2 (enExample)
KR (1) KR20240004519A (enExample)
CN (1) CN117729917A (enExample)
AU (1) AU2021443620A1 (enExample)
BR (1) BR112023020922A2 (enExample)
CA (1) CA3216896A1 (enExample)
IL (1) IL307974A (enExample)
WO (1) WO2022231580A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744168A (zh) * 2022-09-09 2025-04-01 深圳艾欣达伟医药科技有限公司 Ast-3424联用治疗白血病及淋巴瘤
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121646469A (zh) 2023-09-05 2026-03-10 深圳艾欣达伟医药科技有限公司 Ast-3424治疗癌症、肿瘤的给药方案及制药用途
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
CN121049512A (zh) * 2024-05-28 2025-12-02 深圳艾欣达伟医药科技有限公司 Ast-3424治疗肝癌

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) * 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
US20170165364A1 (en) * 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
WO2016145092A1 (en) * 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
KR101985778B1 (ko) * 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
CN118834240A (zh) * 2019-05-13 2024-10-25 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
EP4003314B1 (en) * 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease

Also Published As

Publication number Publication date
KR20240004519A (ko) 2024-01-11
JP7875886B2 (ja) 2026-06-18
CA3216896A1 (en) 2022-11-03
EP4329745A4 (en) 2025-03-19
CN117729917A (zh) 2024-03-19
BR112023020922A2 (pt) 2023-12-12
WO2022231580A1 (en) 2022-11-03
JP2024515809A (ja) 2024-04-10
US20240216401A1 (en) 2024-07-04
EP4329745A1 (en) 2024-03-06
AU2021443620A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL292642A (en) Ras inhibitors
IL311840A (en) Ras inhibitors
IL270886A (en) Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
IL245219B (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
EP3958929C0 (en) PORTABLE INJECTOR
IL290266A (en) Biomarkers for determining the efficacy of immune checkpoint inhibitors
EP4434979A4 (en) KIF18A INHIBITOR
IL264063B (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
MX374633B (es) Combinaciones terapeuticas para usarse en el tratamiento de tumores.
DK3746446T3 (da) PRC2-inhibitorer
EP3890781C0 (en) IMMUNE CHECKPOINT INHIBITOR IN COMBINATION WITH SONODYNAMIC THERAPY
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
IL310863A (en) Spiro indoline inhibitors of kif18a
EP4329745A4 (en) COMBINATION THERAPY USING AN AKR1C3-ACTIVATED COMPOUND WITH AN IMMUNE CHECKPOINT INHIBITOR
CL2022001235S1 (es) Autoinyector portátil
EP4351552A4 (en) COMBINATION THERAPIES WITH SETD2 INHIBITORS
EP4003986A4 (en) Inhibitor compounds
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
IL289592A (en) Methods for diagnosing the effectiveness of anti-tumor treatment
EP4168398A4 (en) TYK-2 INHIBITOR
EP4223512A4 (en) LAMINATE
EP4140738A4 (en) LAMINATE
EP4090369A4 (en) PERICYTE-SPARKING THERAPY